Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome
Background: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [±] RBV) regimens and to evaluate the associat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Biomedical and Biotechnology Research Journal |
| Subjects: | |
| Online Access: | http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2022;volume=6;issue=1;spage=109;epage=116;aulast=Ibrahim |
| _version_ | 1798019657015230464 |
|---|---|
| author | Hany Mohammed Ibrahim Faten Roshdy Abdel-Ghaffar Ahmed Bahgat Zied Sameha Husni El-Ghareeb |
| author_facet | Hany Mohammed Ibrahim Faten Roshdy Abdel-Ghaffar Ahmed Bahgat Zied Sameha Husni El-Ghareeb |
| author_sort | Hany Mohammed Ibrahim |
| collection | DOAJ |
| description | Background: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [±] RBV) regimens and to evaluate the association of interferon-gamma induced protein 10 (IP-10) and macrophage inflammatory-1-beta (MIP-1β) and C-reactive protein (CRP) with treatment responses as potential biomarkers for the prognosis of HCV in patients from Kafer EL-Sheikh Province, Egypt. Methods: HCV Patients were treated with a combined treatment of SOF plus DCV with or without RBV for 12 weeks. The biochemical, hematological parameters, HCV RNA load, IP-10, MIP-1β, and CRP were detected pre- and post-treatment. Results: Both SOF-based regimens improved the liver function, anemia, leukopenia, and thrombocytopenia especially after treatment with SOF, DCV, and RBV. Sustained virological response 12 was slightly higher in the group receiving (SOF and DCV) therapy (99.42%) when compared to (SOF, DCV, and RBV) therapy (98.44%). The most common adverse events were fatigue, headache, anorexia, rash, and nausea. Interestingly, higher levels of the IP-10, MIP-1β, or CRP were observed in the serum of patients with HCV before treatment, and their levels significantly decreased after the treatment of both regimens. Conclusions: Our study revealed that SOF-based regimens are efficacious in controlling the HCV load and IP-10, MIP-1β, or CRP have both bioprognostic efficacy and potential role in predicting treatment responses. |
| first_indexed | 2024-04-11T16:44:17Z |
| format | Article |
| id | doaj.art-ce43dcfdd94146909b6b3ab9409cfe7e |
| institution | Directory Open Access Journal |
| issn | 2588-9834 2588-9842 |
| language | English |
| last_indexed | 2024-04-11T16:44:17Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Biomedical and Biotechnology Research Journal |
| spelling | doaj.art-ce43dcfdd94146909b6b3ab9409cfe7e2022-12-22T04:13:36ZengWolters Kluwer Medknow PublicationsBiomedical and Biotechnology Research Journal2588-98342588-98422022-01-016110911610.4103/bbrj.bbrj_209_21Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcomeHany Mohammed IbrahimFaten Roshdy Abdel-GhaffarAhmed Bahgat ZiedSameha Husni El-GhareebBackground: Hepatitis C virus (HCV) is the most important virus among the infectious agents as the cause of liver disease in Egypt. The aim of this work was to assess the efficacy and tolerability of the sofosbuvir + daclatasvir (±) ribavirin (SOF + DCV [±] RBV) regimens and to evaluate the association of interferon-gamma induced protein 10 (IP-10) and macrophage inflammatory-1-beta (MIP-1β) and C-reactive protein (CRP) with treatment responses as potential biomarkers for the prognosis of HCV in patients from Kafer EL-Sheikh Province, Egypt. Methods: HCV Patients were treated with a combined treatment of SOF plus DCV with or without RBV for 12 weeks. The biochemical, hematological parameters, HCV RNA load, IP-10, MIP-1β, and CRP were detected pre- and post-treatment. Results: Both SOF-based regimens improved the liver function, anemia, leukopenia, and thrombocytopenia especially after treatment with SOF, DCV, and RBV. Sustained virological response 12 was slightly higher in the group receiving (SOF and DCV) therapy (99.42%) when compared to (SOF, DCV, and RBV) therapy (98.44%). The most common adverse events were fatigue, headache, anorexia, rash, and nausea. Interestingly, higher levels of the IP-10, MIP-1β, or CRP were observed in the serum of patients with HCV before treatment, and their levels significantly decreased after the treatment of both regimens. Conclusions: Our study revealed that SOF-based regimens are efficacious in controlling the HCV load and IP-10, MIP-1β, or CRP have both bioprognostic efficacy and potential role in predicting treatment responses.http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2022;volume=6;issue=1;spage=109;epage=116;aulast=Ibrahimc-reactive proteindaclatasviregyptinduced protein 10macrophage inflammatory-1-betaribavirinsofosbuvir |
| spellingShingle | Hany Mohammed Ibrahim Faten Roshdy Abdel-Ghaffar Ahmed Bahgat Zied Sameha Husni El-Ghareeb Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome Biomedical and Biotechnology Research Journal c-reactive protein daclatasvir egypt induced protein 10 macrophage inflammatory-1-beta ribavirin sofosbuvir |
| title | Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome |
| title_full | Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome |
| title_fullStr | Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome |
| title_full_unstemmed | Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome |
| title_short | Assessment of the sofosbuvir + daclatasvir (±) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients' therapy outcome |
| title_sort | assessment of the sofosbuvir daclatasvir ribavirin treatment and the prognostic efficacy of interferon gamma induced protein 10 macrophage inflammatory 1 beta and c reactive protein in hepatitis c egyptian patients therapy outcome |
| topic | c-reactive protein daclatasvir egypt induced protein 10 macrophage inflammatory-1-beta ribavirin sofosbuvir |
| url | http://www.bmbtrj.org/article.asp?issn=2588-9834;year=2022;volume=6;issue=1;spage=109;epage=116;aulast=Ibrahim |
| work_keys_str_mv | AT hanymohammedibrahim assessmentofthesofosbuvirdaclatasvirribavirintreatmentandtheprognosticefficacyofinterferongammainducedprotein10macrophageinflammatory1betaandcreactiveproteininhepatitiscegyptianpatientstherapyoutcome AT fatenroshdyabdelghaffar assessmentofthesofosbuvirdaclatasvirribavirintreatmentandtheprognosticefficacyofinterferongammainducedprotein10macrophageinflammatory1betaandcreactiveproteininhepatitiscegyptianpatientstherapyoutcome AT ahmedbahgatzied assessmentofthesofosbuvirdaclatasvirribavirintreatmentandtheprognosticefficacyofinterferongammainducedprotein10macrophageinflammatory1betaandcreactiveproteininhepatitiscegyptianpatientstherapyoutcome AT samehahusnielghareeb assessmentofthesofosbuvirdaclatasvirribavirintreatmentandtheprognosticefficacyofinterferongammainducedprotein10macrophageinflammatory1betaandcreactiveproteininhepatitiscegyptianpatientstherapyoutcome |